nach oben

Arthritis Research & Therapy

Erschienen in:

01.04.2002 | Supplement

Autoantibodies in rheumatoid arthritis and their clinical significance

verfasst von: Günter Steiner, Josef Smolen

Erschienen in: Arthritis Research & Therapy | Sonderheft 2/2002

Einloggen, um Zugang zu erhalten

Abstract

Autoantibodies are proven useful diagnostic tools for a variety of rheumatic and non-rheumatic autoimmune disorders. However, a highly specific marker autoantibody for rheumatoid arthritis (RA) has not yet been determined. The presence of rheumatoid factors is currently used as a marker for RA. However, rheumatoid factors have modest specificity (~70%) for the disease. In recent years, several newly characterized autoantibodies have become promising candidates as diagnostic indicators for RA. Antikeratin, anticitrullinated peptides, anti-RA33, anti-Sa, and anti-p68 autoantibodies have been shown to have >90% specificity for RA. These autoantibodies are reviewed and the potential role of the autoantibodies in the pathogenesis of RA is briefly discussed.

von Muhlen CA, Tan EM: Autoantibodies in the diagnosis of systemic rheumatic disease. Semin Arthritis Rheum. 1995, 24: 323-358. 10.1016/S0049-0172(95)80004-2.PubMedCrossRef

Arbuckle MR, James JA, Kohlhase KF, Rubertone MV, Dennis GJ, Harley JB: Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol. 2001, 54: 211-219. 10.1046/j.1365-3083.2001.00959.x.PubMedCrossRef

Gussin HA, Ignat GP, Varga J, Teodorescu M: Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 2001, 44: 376-383. 10.1002/1529-0131(200102)44:2<376::AID-ANR56>3.0.CO;2-2.PubMedCrossRef

Nishikai M, Ohya K, Kosaka M, Akiya K, Tojo T: Anti-Jo-1 antibodies in polymyositis or dermatomyositis: evaluation by ELISA using recombinant fusion protein Jo-1 as antigen. Br J Rheumatol. 1998, 37: 357-361. 10.1093/rheumatology/37.4.357.PubMedCrossRef

van der Geld YM, Limburg PC, Kallenberg CG: Proteinase 3, Wegener's autoantigen: from gene to antigen. J Leukoc Biol. 2001, 69: 177-190.PubMed

Smolen JS: Rheumatoid arthritis. In Manual of Biological Markers of Disease. Edited by: Maini RN, van Venrooij WJ. 1996, Amsterdam: Kluwer Academic Publishers, 1-18.

Schett G, Hayer S, Tohidast-Akrad M, Schmid BJ, Lang S, Turk B, Kainberger F, Haralambous S, Kollias G, Newby AC, Xu Q, Steiner G, Smolen J: Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. Arthritis Rheum. 2001, 44: 2888-2898. 10.1002/1529-0131(200112)44:12<2888::AID-ART477>3.0.CO;2-3.PubMedCrossRef

Tighe H, Carson DA: Rheumatoid factors. In Textbook of Rheumatology. Edited by: Kelley WN, Harris ED, Ruddy S, Sledge CB. 1997, Philadelphia, PA: WB Saunders, 241-249. 5

Youinou P, Serre G: The antiperinuclear factor and antikeratin antibody systems. Int Arch Allergy Immunol. 1995, 107: 508-518.PubMedCrossRef

10.

Dumortier H, Monneaux F, Jahn-Schmid B, Briand JP, Skriner K, Cohen PL, Smolen JS, Steiner G, Muller S: B and T cell responses to the spliceosomal heterogeneous nuclear ribonucleoproteins A2 and B1 in normal and lupus mice. J Immunol. 2000, 165: 2297-2305.PubMedCrossRef

11.

Eisenberg RA, Thor LT, Dixon FJ: Serum-serum interactions in autoimmume mice. Arthritis Rheum. 1979, 22: 1074-1081.PubMedCrossRef

12.

Koopman WJ, Gay S: The MRL-lpr/lpr mouse. A model for the study of rheumatoid arthritis. Scand J Rheumatol. 1988, 75: 284-289.CrossRef

13.

Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ: Anti-keratin antibodies in rheumatoid arthritis. Br Med J. 1979, 14: 97-99.CrossRef

14.

Cordonnier C, Meyer O, Palazzo E, de Bandt M, Elias A, Nicaise P, Haim T, Kahn MF, Chatellier G: Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol. 1996, 35: 620-624.PubMedCrossRef

15.

Simon M, Girbal E, Sebbag M, Gomes-Daudrix V, Vincent C, Salama G, Serre G: The cytokeratin filament-aggregating protein filaggrin is the target of the so-called 'antikeratin antibodies', autoantibodies specific for rheumatoid arthritis. J Clin Invest. 1993, 92: 1387-1393.PubMedPubMedCentralCrossRef

16.

Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998, 101: 273-281.PubMedPubMedCentralCrossRef

17.

Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson Bessiere C, Jolivet Reynaud C, Jolivet M, Serre G: The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol. 1999, 162: 585-594.PubMed

18.

Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, Steiner G, Rosen A, Zhang C, Menard HA, Zhou ZJ, Palosua T, van Venrooij WJ, Wilder RL, Klippel JH, Schumacher HR, El Gabalawy HS: Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000, 2: 236-243. 10.1186/ar93.PubMedPubMedCentralCrossRef

19.

Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000, 43: 155-163. 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3.PubMedCrossRef

20.

Masson-Bessiere C, Sebbag M, Durieux JJ, Nogueira L, Vincent C, Girbal Neuhauser E, Durroux R, Cantagrel A, Serre G: In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol. 2000, 119: 544-552. 10.1046/j.1365-2249.2000.01171.x.PubMedPubMedCentralCrossRef

21.

Hassfeld W, Steiner G, Hartmuth K, Kolar Z, Scherak O, Graninger W, Thumb N, Smolen J: Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum. 1989, 32: 1515-1520.PubMedCrossRef

22.

Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, Serre G: The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol. 2001, 166: 4177-4184.PubMedCrossRef

23.

Steiner G, Hartmuth K, Skriner K, Maurer-Fogy I, Sinski A, Thal-mann E, Hassfeld W, Barta A, Smolen JS: Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest. 1992, 90: 1061-1066.PubMedPubMedCentralCrossRef

24.

Meyer O, Tauxe F, Fabregas D, Gabay C, Goycochea M, Haim T, Elias A, Kahn MF: Anti-RA 33 antinuclear autoantibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies. Clin Exp Rheumatol. 1993, 11: 473-478.PubMed

25.

Hassfeld W, Steiner G, Studnicka-Benke A, Skriner K, Graninger W, Fischer I: Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum. 1995, 38: 777-785.PubMedCrossRef

26.

Hassfeld W, Steiner G, Graninger W, Witzmann G, Schweitzer H, Smolen JS: Autoantibody to the nuclear antigen RA33: A marker for early rheumatoid arthritis. Br J Rheumatol. 1993, 32: 199-203.PubMedCrossRef

27.

Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000, 43: 2383-2390. 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D.PubMedCrossRef

28.

Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD: In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol. 2001, 167: 6821-6826.PubMedCrossRef

29.

Despres N, Boire G, Lopez-Longo FJ, Menard HA: The Sa system: a novel antigen–antibody system specific for rheumatoid arthritis. J Rheumatol. 1994, 21: 1027-1033.PubMed

30.

Hueber W, Hassfeld W, Smolen JS, Steiner G: Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford). 1999, 38: 155-159. 10.1093/rheumatology/38.2.155.CrossRef

31.

Hayem G, De Bandt M, Palazzo E, Roux S, Combe B, Eliaou JF, Sany J, Kahn MF, Meyer O: Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol. 1999, 26: 7-13.PubMed

32.

Blass S, Specker C, Lakomek HJ, Schneider EM, Schwochau M: Novel 68 kDa autoantigen detected by rheumatoid arthritis specific antibodies. Ann Rheum Dis. 1995, 54: 355-360.PubMedPubMedCentralCrossRef

33.

Blass S, Union A, Raymackers J, Schumann F, Ungethum U, Müller Steinbach S, De Keyser F, Engel JM, Burmester GR: The stress protein BiP is over expressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum. 2001, 44: 761-771. 10.1002/1529-0131(200104)44:4<761::AID-ANR132>3.0.CO;2-S.PubMedCrossRef

34.

Weyand CM, Goronzy JJ: Pathogenesis of rheumatoid arthritis. Med Clin North Am. 1997, 81: 29-55. 10.1016/S0025-7125(05)70504-6.PubMedCrossRef

35.

Smolen JS, Steiner G: Are autoantibodies active players of epiphenomena?. Curr Opin Rheumatol. 1998, 10: 201-206.PubMedCrossRef

36.

Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, Benoist C, Mathis D: From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999, 10: 451-561. 10.1016/S1074-7613(00)80045-X.PubMedCrossRef

37.

Matsumoto I, Staub A, Benoist C, Mathis D: Arthritis provoked by linked T and B cell recognition of glycolytic enzyme. Science. 1999, 26: 1732-1735. 10.1126/science.286.5445.1732.CrossRef

38.

Schaller M, Burton DR, Ditzel HJ: Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol. 2001, 2: 746-753. 10.1038/90696.PubMedCrossRef

Titel: Autoantibodies in rheumatoid arthritis and their clinical significance
verfasst von: Günter Steiner
Josef Smolen
Publikationsdatum: 01.04.2002
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe Sonderheft 2/2002
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar551

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2002

The determination and measurement of functional disability in rheumatoid arthritis

Current and future management approaches for rheumatoid arthritis

Structural damage in rheumatoid arthritis as visualized through radiographs

Magnetic resonance imaging: opportunities for rheumatoid arthritis disease assessment and monitoring long-term treatment outcomes

How does infliximab work in rheumatoid arthritis?